Manara - Qatar Research Repository
2 files

Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug Arsenal

journal contribution
submitted on 2024-05-15, 12:19 and posted on 2024-05-15, 12:21 authored by Nehme El-Hachem, Edward Eid, Georges Nemer, Ghassan Dbaibo, Ossama Abbas, Nelly Rubeiz, Salah Zeineldine, Ghassan M. Matar, Jean-Pierre Bikorimana, Riam Shammaa, Benjamin Haibe-Kains, Mazen Kurban, Moutih Rafei

The beginning of the 21st century has been marked by three distinct waves of zoonotic coronavirus outbreaks into the human population. The COVID-19 (coronavirus disease 2019) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and emerged as a global threat endangering the livelihoods of millions worldwide. Currently, and despite collaborative efforts, diverse therapeutic strategies from ongoing clinical trials are still debated. To address the need for such an immediate call of action, we leveraged the largest dataset of drug-induced transcriptomic perturbations, public SARS-CoV-2 transcriptomic datasets, and expression profiles from normal lung transcriptomes. Most importantly, our unbiased systems biology approach prioritized more than 50 repurposable drug candidates (e.g., corticosteroids, Janus kinase and Bruton kinase inhibitors). Further clinical investigation of these FDA-approved candidates as monotherapy or in combination with an antiviral regimen (e.g., remdesivir) could lead to promising outcomes in patients with COVID-19.

Other Information

Published in: iScience
See article on publisher's website:



  • English


Cell Press

Publication Year

  • 2020

License statement

This Item is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Institution affiliated with

  • Hamad Bin Khalifa University
  • College of Health and Life Sciences - HBKU